Final Approval of $264 Million Settlement with Mylan Defendants Granted in EpiPen Class Action, Resulting in Total Recovery of $609 Million for the Class

July 11, 2022 – Judge Daniel D. Crabtree has granted final approval to the $264 million settlement between Plaintiffs and the Mylan Defendants in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, finding the settlement to be fair, reasonable, and adequate. The settlement resolves class claims that Mylan, together with the Pfizer Defendants, engaged in anticompetitive behavior that resulted in huge increases in the price of auto-injectable EpiPen devices, which are used to treat life-threatening allergic reactions.

Plaintiffs previously settled with Pfizer for $345 million. Together, the settlements with Mylan and Pfizer amount to a total recovery of $609 million for the class. Class members who submitted a claim pursuant to the Pfizer settlement are automatically eligible to receive a payment from the Mylan settlement.

Pritzker Levine partner Elizabeth C. Pritzker serves as Co-Lead Class Counsel in the case, which is proceeding in the United States District Court for the District of Kansas. In his order granting final approval, Judge Crabtree praised Co-Lead Counsel for obtaining “substantial relief” for the class and for performing “exceptional legal work” with “skill and zeal.”

About Pritzker Levine

Pritzker Levine LLP is national litigation firm with offices in California and New York. The firm serves corporate clients, public entities, pension funds, small businesses, nonprofit groups, labor unions, whistleblowers and injured persons in cases involving antitrust violations, securities fraud and derivative claims, commercial disputes, consumer protection, financial wrongdoing, employment law and personal injuries.